Naohito Fujishima

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Hagop M. Kantarjian, Daniel J. DeAngelo, Anjali S. Advani et al. · The Lancet Haematology · 2017 · 209 citations

Inotuzumab Ozogamicin, Hematological Malignancy, Oncology +9

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

Naoto Takahashi, Masatomo Miura, Stuart A. Scott et al. · Journal of Human Genetics · 2010 · 162 citations · Full text

Hematological Malignancy, Oncology, Medicine +9

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

Saiko Kurosawa, T Yamaguchi, S Miyawaki et al. · Haematologica · 2010 · 107 citations · Full text

Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group

M. Hirokawa, K Sawada, Naohito Fujishima et al. · Haematologica · 2007 · 103 citations · Full text

Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group

K Sawada, Mitsuyoshi Hirokawa, Naohito Fujishima et al. · Haematologica · 2007 · 96 citations · Full text